Recent News

• 08.06.2026 - Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
• 06.10.2026 - Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
• 05.07.2026 - Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
• 04.23.2026 - Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
• 03.02.2026 - Tectonic Therapeutic to Participate in March Investor Conferences
• 02.26.2026 - Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• 02.23.2026 - Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
• 02.11.2026 - Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
• 12.01.2025 - Tectonic Therapeutic to Participate in December Investor Conferences
• 11.06.2025 - Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights

Recent Filings

• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 144 Report of proposed sale of securities
• 06.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities